Reviva Pharmaceuticals Holdings Inc (RVPH)

Apr 07, 2025

RVPH: M&A Deals Highlight Brilaroxazine Value - MSN

Apr 07, 2025

Apr 07, 2025

What is Roth Capital’s Forecast for RVPH Q1 Earnings? - Defense World

Apr 07, 2025

Apr 04, 2025

Biopharma Firm Discovers High-Impact CNS Therapy in U.S. With Breakthrough Results - streetwisereports.com

Apr 04, 2025

Apr 02, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Price Target Lowered to $8.00 at D. Boral Capital - Defense World

Apr 02, 2025

Apr 02, 2025

Reviva Pharmaceuticals Reports 2024 Financial Results - TipRanks

Apr 02, 2025

Apr 01, 2025

RVPH stock touches 52-week low at $0.6 amid market challenges - Investing.com Australia

Apr 01, 2025

Apr 01, 2025

Ulta Beauty To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Apr 01, 2025

Mar 31, 2025

Reviva Pharmaceuticals Delays Annual Report Filing - TipRanks

Mar 31, 2025

Mar 31, 2025

Reviva Pharmaceuticals Holdings Files For Non-Timely 10-KSEC Filing - MarketScreener

Mar 31, 2025

Mar 31, 2025

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights - GlobeNewswire

Mar 31, 2025

Mar 31, 2025

Breakthrough: Reviva's Schizophrenia Treatment Delivers Powerful 1-Year Results, Losses Narrow - Stock Titan

Mar 31, 2025

Mar 30, 2025

Reviva to Present Brilaroxazine Topline Data for Long-Term - GlobeNewswire

Mar 30, 2025

Mar 30, 2025

Major Clinical Data: 52-Week Results for New Schizophrenia Drug Coming at SIRS 2025 - Stock Titan

Mar 30, 2025

Mar 27, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price Down 3.5% – What’s Next? - Defense World

Mar 27, 2025

Mar 07, 2025

Schizophrenia Drugs Market: Top Competitors, Market Share, - openPR.com

Mar 07, 2025

Mar 02, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Rating of “Buy” from Brokerages - Defense World

Mar 02, 2025

Feb 18, 2025

Reviva Pharmaceuticals adjusts executive pay, grants stock options By Investing.com - Investing.com South Africa

Feb 18, 2025

Feb 18, 2025

Reviva Pharmaceuticals adjusts executive pay, grants stock options - Investing.com India

Feb 18, 2025

Feb 18, 2025

Reviva Pharmaceuticals Approves Executive Compensation Changes - TipRanks

Feb 18, 2025

Feb 12, 2025

Unusually active option classes on open February 12th - TipRanks

Feb 12, 2025

Feb 10, 2025

Get in on Reviva Pharmaceuticals Holdings Inc’s (RVPH) buy-in window today! - SETE News

Feb 10, 2025

Feb 08, 2025

Analysts Set Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) PT at $11.40 - MarketBeat

Feb 08, 2025

Feb 06, 2025

Adversity is less terrifying than hope: Reviva Pharmaceuticals Holdings Inc (RVPH) - SETE News

Feb 06, 2025

Feb 05, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Receives Average Recommendation of “Buy” from Analysts - Defense World

Feb 05, 2025

Feb 05, 2025

How should investors view Reviva Pharmaceuticals Holdings Inc (RVPH)? - US Post News

Feb 05, 2025

Feb 04, 2025

Reviva Pharmaceuticals Holdings Inc (RVPH) Stock: A Comprehensive 52-Week Review - The InvestChronicle

Feb 04, 2025

Feb 04, 2025

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Marketscreener.com

Feb 04, 2025

Feb 04, 2025

Reviva Pharmaceuticals to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12, 2025 - Nasdaq

Feb 04, 2025

Feb 04, 2025

Reviva CEO to Showcase CNS Pipeline at Major Healthcare Conference - StockTitan

Feb 04, 2025

Feb 02, 2025

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Sees Significant Decline in Short Interest - MarketBeat

Feb 02, 2025

Jan 31, 2025

Reviva to Participate in the 2025 BIO CEO & Investor Conference - GlobeNewswire

Jan 31, 2025

Jan 30, 2025

Reviva to Participate in the 2025 BIO CEO & Investor Conference -January 30, 2025 at 08:01 am EST - Marketscreener.com

Jan 30, 2025

Jan 30, 2025

Reviva CEO Reveals Next-Gen Mental Health Drug Strategy at Major Biotech Summit - StockTitan

Jan 30, 2025

Jan 29, 2025

Is Reviva Pharmaceuticals Holdings Inc (RVPH) positioned for future growth? - SETE News

Jan 29, 2025

Jan 29, 2025

Reviva Pharmaceuticals Holdings, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R) - ACCESS Newswire

Jan 29, 2025

Jan 25, 2025

HC Wainwright Has Positive Outlook for RVPH FY2024 Earnings - Defense World

Jan 25, 2025

Jan 25, 2025

HC Wainwright Has Bullish Outlook for RVPH FY2024 Earnings - MarketBeat

Jan 25, 2025

Jan 22, 2025

5-HT2 Agonist Clinical Trial Pipeline Appears Robust With 20+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.

Jan 22, 2025

Jan 22, 2025

HC Wainwright Issues Pessimistic Forecast for Reviva Pharmaceuticals (NASDAQ:RVPH) Stock Price - MarketBeat

Jan 22, 2025

Jan 22, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Receives “Buy” Rating from D. Boral Capital - Defense World

Jan 22, 2025

Jan 22, 2025

Reviva Pharmaceuticals' (RVPH) Buy Rating Reaffirmed at D. Boral Capital - MarketBeat

Jan 22, 2025

Jan 22, 2025

Reviva Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:RVPH) - MarketBeat

Jan 22, 2025

Jan 22, 2025

Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH) - Defense World

Jan 22, 2025

Jan 21, 2025

Reviva Pharmaceuticals Unusual Options Activity - Benzinga

Jan 21, 2025

Jan 21, 2025

Stock Traders Purchase Large Volume of Reviva Pharmaceuticals Call Options (NASDAQ:RVPH) - MarketBeat

Jan 21, 2025

Jan 21, 2025

Reviva Pharmaceuticals (NASDAQ:RVPH) Given Buy Rating at D. Boral Capital - MarketBeat

Jan 21, 2025